http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#Head
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#assertion
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#provenance
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#pubinfo
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#assertion
http://purl.obolibrary.org/obo/DOID_10933
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10933
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00176
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
http://www.w3.org/2000/01/rdf-schema#label
fluvoxamine maleate extended release capsules are a selective serotonin reuptake inhibitor ssri indicated for the treatment of obsessive compulsive disorder ocd 1 one 12 week study with fluvoxamine maleate extended release capsules in adults 14 1 two 1 week studies with immediate release ir fluvoxamine tablets in adults and one 1 week study with ir fluvoxamine tablets in children and adolescents 14 1 14 3 one maintenance study with ir fluvoxamine tablets 14 2 fluvoxamine maleate extended release capsules are indicated for the treatment of obsessive compulsive disorder ocd as defined in the dsm iv obsessive compulsive disorder is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are ego dystonic and or repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable the obsessions or compulsions cause marked distress are time consuming or significantly interfere with social or occupational functioning the efficacy of fluvoxamine maleate extended release capsules was demonstrated in one 12 week trial in adults with fluvoxamine maleate extended release capsules as well as in two 1 week trials in adults and in one 1 week trial in children and adolescents ages 8 to 17 years with immediate release fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsm iv or dsm iii r see clinical studies 14 1 14 3 the efficacy of fluvoxamine for long term use was established in one maintenance study in adults with immediate release fluvoxamine tablets see clinical studies 14 2 see dosage and administration 2 4
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00176
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#provenance
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#pubinfo
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig
http://purl.org/nanopub/x/hasSignature
daAZGH0ECZQNgAa8GNevtKAjSlmOXgmBCSE16gOjkpKlcJc0rFT6m6T0Bd0dfvC0XAlLfS24R8a+SWB2/ksB0tP+jABwWpIGBje0nd5bqh7ePRmLHVmC37Jrf7+MraC8xOwQwODcG3pX6I41fdb4X1kpgMzjzLIdi8vN3sIgOrc=
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://purl.org/dc/terms/created
2021-06-14T09:03:15.697+02:00
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs